NCT07282665

A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2025-12-10Est. Completion: 2028-12-11

Enrollment target: 32,500 participants

Locations

North Alabama Research Center, Athens, Alabama, United States
Lakeview Clinical Research, Guntersville, Alabama, United States
Medical Affiliated Research Center, Huntsville, Alabama, United States
Chinle Center for Indigenous Health, Chinle, Arizona, United States
Chinle Comprehensive Health Care Facility, Chinle, Arizona, United States
Epic Medical Research-Sun City, Sun City, Arizona, United States
Applied Research Center of Arkansas, Little Rock, Arkansas, United States
Kaiser Permanente Daly City, Daly City, California, United States
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
Kaiser Permanente Oncology Pharmacy #014C, Los Angeles, California, United States
Sacramento VA Medical Center, Mather, California, United States
Kaiser Permanente Oakland, Oakland, California, United States
Kaiser Permanente Ontario Medical Center, Ontario, California, United States
Kaiser Permanente Roseville, Roseville, California, United States
Kaiser Permanente Sacramento, Sacramento, California, United States

Clostridioides Difficile InfectionClostridioides Difficile Infection RecurrenceClostridoides Difficile Associated Disease

Re-exposure to systemic antibiotics (i.e., antibiotics absorbed into the bloodstream) is common after a Clostridioides d…

Montreal, CanadaEst. completion Oct 1, 2028

Clostridoides Difficile Associated Disease

An antibody is a substance your body makes to fight off infection. This study will explore the safety and antibody respo…

Phoenix, United StatesEst. completion Jun 19, 2031

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.